Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

After Losing Over $16 Billion Of Market Capitalization Edwards Lifesciences (EW) Faces Investor Class Action – Hagens Berman

SAN FRANCISCO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Edwards Lifesciences Corporation (NYSE: EW) investors who suffered substantial losses to submit your losses now.

Class Period: Feb. 6, 2024 – July 24, 2024
Lead Plaintiff Deadline: Dec. 13, 2024
Visit: www.hbsslaw.com/investor-fraud/ew
Contact the Firm Now: EW@hbsslaw.com
                                          844-916-0895

Class Action Lawsuit Against Edwards Lifesciences Corporation (EW):

The litigation is focused on the propriety of Edwards Lifesciences’ disclosures about its core product, the Transcatheter Aortic Valve Replacement (“TAVR”) platform.

More specifically, throughout the Class Period, Edwards Lifesciences repeatedly assured investors that its TAVR platform was positioned for “strong sustainable growth” well into the future, it could “accelerate growth in 2025 and beyond[,]” TAVR could grow healthy double digit, and it could capitalize on the large percentage of undertreated patients with severe aortic stenosis.

The complaint alleges that the company made misleading statements and failed to disclose that: (i) it did not possess reliable information supportive of its TAVR revenue and growth outlook; (ii)
TAVR growth was at risk of decelerating; and (iii) its “patient activation activities” did not reach the low-treatment-rate population.

Investors learned the truth on July 24, 2024, when Edwards Lifesciences announced its Q2 2024 financial results. Among other things, the company revealed that its TAVR sales grew just 5% and slashed its TAVR growth guidance to 5 to 7% from 8 to 10%.

The company blamed the TAVR setback on “[t]he continued growth and expansion of structural heart therapies, including newly approved tricuspid therapies and other fast-growing structural heart therapies put pressure on hospital workflows, which impacted TAVR.”

The next day, July 25, 2024, several analysts downgraded Edwards Lifesciences shares and reduced their price targets. One analyst wrote, “[m]anagement talked about physician capacity as the issue versus demand, but we struggle with that explanation [….] [b]ecause aortic stenosis has a higher mortality […] management looks to be implying that doctors could be prioritizing lower mortality patients over higher mortality ones – which we struggle to understand.”

These events drove the price of Edwards Lifesciences shares down $27.25 (-31%) on July 25, 2024, wiping out over $16 billion of shareholder value in a single day.

“We’re investigating whether Edwards Lifesciences may have misled investors about the true business and growth prospects for TAVR amid an apparently increasing competitive market,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Edwards Lifesciences and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to frequently asked questions about the Edwards Lifesciences case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding Edwards Lifesciences should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email EW@hbsslaw.com.

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw

Contact:
Reed Kathrein, 844-916-0895


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.